Alcohol Abuse and De Novo Tumors in Liver Transplantation

Zanus, Giacomo; Carraro, Amedeo; Vitale, Alessandro; Gringeri, Enrico; D’Amico, F.; Valmasoni, Michele; D’Amico, F.; Brolese, Alberto; Boccagni, Patrizia; Neri, Daniele; Srsen, N; Burra, Patrizia; Feltracco, Paolo; Bonsignore, Pasquale; Scopelliti, Michele; Cillo, Umberto

doi:10.1016/j.transproceed.2009.03.055

Cited by 12 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common solid organ cancers in our study were non‐small cell lung cancer and squamous cell cancer of the head and neck accounting for 37% of all non‐skin de novo malignancies. Increased risk of aerodigestive cancers post–liver transplant is well described in patients with a history of tobacco use and alcoholic liver disease . In our cohort, tobacco use was the more important risk factor, but this may be related to a proportion of patients continuing to use tobacco post‐transplant, where as the majority of patients with alcoholic liver disease would have maintained abstinence post‐transplant.…”

Section: Discussionmentioning

confidence: 76%

De novo malignancy post–liver transplantation: a single center, population controlled study

Chatrath

Berman

Vuppalanchi

et al. 2013

Clinical Transplantation

View full text Add to dashboard Cite

Background With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. Aim To characterize the incidence of de novo malignancy after liver transplantation compared to a control non-transplant population. Methods We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010 The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared to age, gender and period matched state population using the Indiana State Cancer Registry. Results After a mean follow up of 5.7 ± 3.2 years, 73 patients (13.7%) developed 80 cancers, with 5 and 10 year incidence rates of 11.7%, and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared to matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR:3.1, 95%CI:2.9–3.2), skin (melanoma) (SIR:5.8, 95%CI:4.7–7.0), hematologic (SIR:7.1, 95%CI:6.3–8.0), and solid (SIR:2.7, 95%CI:2.5–2.8) tumors. Conclusion There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.

show abstract

Section: Discussionmentioning

confidence: 76%

De novo malignancy post–liver transplantation: a single center, population controlled study

Chatrath

Berman

Vuppalanchi

et al. 2013

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…13 Fourth, unhealthy life styles might predispose to the oncogenesis of de novo gastric cancer. Previous studies have reported that smoking, alcohol consumption, and poor eating habits were considered to increase the risk of developing de novo malignancy, 14–17 due to the impairment of gastric mucosa. 18,19 And alcohol is hypothesized to decrease natural killer cell activity and promote tumor metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…18,19 And alcohol is hypothesized to decrease natural killer cell activity and promote tumor metastasis. 17,20 Finally, but the most importantly, immunosuppression treatment is strongly associated with the development of de novo gastric cancer when compared with the immunocompetent population. 16,21 Long-term use of immunosuppressive drugs, such as thiopurines and Tacrolimus that are often used after transplantation, could increase the risk of cancer directly with unknown mechanisms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lessons Learned From a Case of Gastric Cancer After Liver Transplantation for Hepatocellular Carcinoma

Yang¹,

Zhu²,

Chen³

et al. 2016

Medicine

View full text Add to dashboard Cite

Nowadays, de novo malignancies have become an important cause of death after transplantation. According to the accumulation of cases with liver transplantation, the incidence of de novo gastric cancer is anticipated to increase among liver transplant recipients in the near future, especially in some East Asian countries where both liver diseases requiring liver transplantation and gastric cancer are major burdens. Unfortunately, there is limited information regarding the relationship between de novo gastric cancer and liver transplantation. Herein, we report a case of stage IIIc gastric cancer after liver transplantation for hepatocellular carcinoma, who was successfully treated by radical distal gastrectomy with D2 lymphadenectomy but died 15 months later due to tumor progression. Furthermore, we extract some lessons to learn from the case and review the literatures.The incidence of de novo gastric cancer following liver transplantations is increasing and higher than the general population. Doctors should be vigilant in early detection and control the risk factors causing de novo gastric cancer after liver transplantation. Curative gastrectomy with D2 lymphadenectomy is still the mainstay of treatment for such patients. Preoperative assessments, strict postoperative monitoring, and managements are mandatory. Limited chemotherapy could be given to the patients with high risk of recurrence. Close surveillance, early detection, and treatment of posttransplant cancers are extremely important and essential to improve the survival.

show abstract

“…Similar to those who have received liver transplantation for other causes, patients who have received liver transplantation due to ALD exhibit a high incidence of de novo cancer in other areas of the body 293,295,301,320-322. Such de novo cancers are associated with an increased mortality following transplantation.…”

Section: Liver Transplantationmentioning

confidence: 99%

KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease

2013

Clin Mol Hepatol

View full text Add to dashboard Cite

Alcohol Abuse and De Novo Tumors in Liver Transplantation

Cited by 12 publications

References 14 publications

De novo malignancy post–liver transplantation: a single center, population controlled study

De novo malignancy post–liver transplantation: a single center, population controlled study

Lessons Learned From a Case of Gastric Cancer After Liver Transplantation for Hepatocellular Carcinoma

KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease

Contact Info

Product

Resources

About